Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Executive Summary

CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.


Related Content

Sarepta’s ESSENCE Trial Gets FDA Panel Nod For Protocol Changes
Sarepta Trial Protocol Changes May Ignite Debate On Placebo Design
Looser Efficacy Standards Could Waste Taxpayer Dollars On Useless Drugs, NEJM Says
Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs
Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
Eteplirsen Review Timeline: CDER Director Was Involved Early And Often
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
Sarepta, FDA And The Dangers Of Strong Early Results
Duchenne Muscular Dystrophy: Second Product Isn't The Charm


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst